body, where translation and transcription are then altered to promote nerve health and function. A large body of literature now demonstrates that the nerve and the end-organ mutually support each other's maintenance. 3 The failure of retrograde transport has been clearly shown to be a primary cause of peripheral neuropathies such as those caused by diabetes, 4, 5 neurotoxic chemotherapy agents, 6 compressive neuropathy, 7, 8 and amyotrophic lateral sclerosis.
D ESPITE A LARGE CLINICAL NEED
, no suitable contrast agent is available for visualizing peripheral nerve tissues by imaging. Numerous nerve diseases could be better diagnosed and treated if clinical neurography could be performed effectively and reliably. Current methods for imaging nerves such as ultrasonography and magnetic resonance imaging (MRI) do exist but are limited and could be improved by the use of a suitable contrast agent. 1 A contrast agent for neurography should preferably be based on a robust physiologic mechanism that is present in all nerves and closely tied to the health of nerve tissues. One such mechanism is the two-way cycle of communication between peripheral nerves and their end-organs fi rst proposed by Levi-Montalcini and Hamburger ( Figure 1A ). 2 In this cycle, action potentials in the nerve lead to synaptic neurotransmitter release, which gives rise to end-organ activity; over long periods, this activity will lead to hypertrophy of the end-organ. The end-organ, in turn, secretes neurotrophic factors that are absorbed by the nerve, and these factors are retrogradely transported to the nerve cell Figure 1 . A , The nerve-end organ cycle of communication. There is continuous interplay between neurons and their end-organs, with nerve stimulation making up one leg and retrograde transport of nerve growth factors the other leg of the cycle. The health and maintenance of both the nerve and the innervated end-organ rely on unbroken mutual communication. B , The crystallographic structure of the nontoxic tetanus toxin C fragment (TTc) is demonstrated at a resolution of 1.61 angstrom. 17 Additional crystallographic studies have suggested that TTc binds by cross-linking to gangliosides in the cell membranes of nerve terminals. 18 C , Characterization of labeled TTc. Top panel: Protein integrity and immunoreactivity of commercially available TTc and recombinant purifi ed TTc are compared. An SDS-PAGE gel demonstrates commercially available TTc ( lane 1 ), recombinant TTc with a His tag ( lane 2 ), fl uorescently labeled TTc with His tag ( lane 3 ), and human serum albumin (HSA) used in this study as a negative control ( lane 4 ). The commercial and purifi ed TTc both run at 50 kDa, and the natively purifi ed protein used in this study did not show any degradation during the purifi cation or fl uorescent labeling process. The immunoreactivity of commercially available TTc ( lane 5 ) and TTc with His tag used in this study ( lane 6 ) was identical and was retained after fl uorescent labeling ( lane 7 ), whereas HSA ( lane 8 ), the control protein, was not. Fluorescently labeled TTc ( lane 9 ) was also visible when fl uorescently scanning the electrophoresis gel, demonstrating the tight covalent association between TTc and the fl uorophore. Lower panel: PC-12 cells cultured under differentiating conditions avidly took up both commercial TTc ( left image ) and recombinant TTc ( middle image ) used in this study but not in HSA ( right image ). 14 This protein is identical to the original published sequences, 15, 16 except for six histidine residues appended to the N-terminus to enable affi nity chromatography purifi cation. The crystallographic structure has been solved ( Figure 1B ), 17 and a putative ligand-receptor interaction with nerve terminal membrane gangliosides has been demonstrated with crystallography. 18 The 50 kDa Histagged protein was purifi ed in its native state using standard procedures 19 and labeled with Alexa Fluor succinimidyl esters 546, 680, and 790 according to the manufacturer's protocol (Invitrogen, Carlsbad, CA). Fluorophores emitting at 546 and 680 nm were used for microscopic studies, whereas the 790 nm probe was used for in vivo studies. The properties of labeled TTc were compared with those of commercially available TTc (Roche Applied Science; Indianapolis, IN) by Western blot and cell uptake studies using PC-12 pheochromocytoma cells (American Type Culture Collection, Manassas, VA) cultured in poly-l -lysine-coated Costar 96-well plates at 2,000 cells/well and differentiated with 50 ng/mL nerve growth factor (Invitrogen). Cellular uptake of TTc-Alexa680 was compared with that of labeled human serum albumin (HSA-Alexa680) by live imaging over a period of 60 minutes. Imaging was performed using an inverted Olympus FV1000 scanning confocal microscope (Olympus America Inc, Center Valley, PA) equipped with the following lasers: multiline Ar laser (457 nm, 488 nm, 515 nm), green HeNe (543 nm), and red HeNe (633 nm) (Melles Griot, Albuquerque, NM).
In Vivo and Ex Vivo Imaging
All animal experiments were performed in compliance with National Institutes of Health and institutional guidelines. Sixty female C57BL/6 mice purchased from Charles River Laboratories (Wilmington, MA) were used in the experiments. Dose-fi nding and imaging studies were performed on 24 animals and histologic studies on 36 animals. Animals were anesthetized using isofl urane (Abbott Laboratories, North Chicago, IL), and their dorsal fur was removed with hair removal cream. The mice underwent injections in their calf muscles with 10, 30, or 100 μg of fl uorescent compound using Hamilton glass syringes with 26-gauge needles mounted on a stereotactic frame. Animals were placed into the whole-body animal imaging system (Xenogen IVIS 200, Caliper Life Sciences, Hopkinton, MA) equipped with the appropriate bandpass excitation and emission fi lters (DsRed for Alexa Fluor 546, 500-550/575-650 nm; Cy5.5 for Alexa Fluor 680, 615-665/695-770 nm; and ICG for Alexa Fluor 790, 710-760/810-875 nm). Images of the dorsal aspects of the animals were taken at specifi c time points under identical conditions: a high fl uorescence level, binning level set at medium, and fi eld of view of 13.1 cm. White light photographs were taken with a 0.2 s/f = 8 exposure and fl uorescence images with a 0.5 s/f = 4 exposure. After animals were killed, tissues including the sciatic nerves and spines were excised, cryopreserved, placed in the small animal imager and imaged using the same parameters as for in vivo imaging. These same tissues were then cryosectioned and used for histological studies. Images were analyzed using the Living Image 3.0 systems software (Caliper Life Sciences). To allow comparison among fl uorescence images obtained during different imaging sessions, fl uorescence normalized to photons per second per centimeter squared per steradian (p s -1 cm -2 sr -1 ) was displayed on the same scale of intensity.
Histologic Analysis and Fluorescence Confocal Microscopy
Excised spines with cords in situ were cut into approximately 5 mm-thick transverse pieces. Serial frozen sections at a thickness of 20 μm were cut in a cryostat. Thoracic spine sections were fi xed in Carnoy fl uid (ethanol:acetic acid, 6:1), permeabilized with 0.1% Tween 20 for 10 minutes, and immersed in hematoxylin QS (Vector Laboratories, Burlingame, CA); stained sections were photographed using an Olympus BX51 microscope (Olympus). For immunohistochemical detection of TTc, 4% paraformaldehyde-fi xed sections were blocked in a solution of phosphate-buffered saline (PBS), 1% bovine serum albumin, and 0.03% Triton X-100, reacted with a polyclonal rabbit anti-TTc antibody (1 μg/mL; Rockland Immunochemicals, Gilbertsville, PA) in blocking buffer containing 0.01% Triton X-100 for 1 hour at room temperature, and incubated with a secondary goat antirabbit Alexa Fluor 488-labeled antibody (1 μg/mL, Invitrogen) at room temperature for 30 minutes. For detection of fl uorescence, sections were mounted in Prolong Gold antifade reagent. Micrographs used were an average of fi ve adjacent slices of a vertical stack captured at 2.5 μm/slice using a 20 × UPLSAPO oil objective with an Olympus FV1000 scanning confocal microscope (Olympus).
Nerves ( n = 12) were cut into 3 mm pieces starting from the nerve insertion into the muscle between the two heads of the gastrocnemius muscle. The tissue pieces were either immediately fi xed in 4% paraformaldehyde, washed with PBS, and mounted with Prolong Gold antifade reagent with DAPI stain (4´,6-diamidino-2-phenylindole, Molecular Probes, Eugene, OR) or embedded in Tissue-Tek OCT compound (Sakura Finetek, Torrance, CA) and imaged and analyzed using confocal microscopy.
Rate of Transport
Animals underwent injections of 30 μg TTc into the right calf muscle and 30 μg HSA into the left calf muscle. Mice were sacrifi ced 20 and 60 minutes after the injection ( n = 5 per time point), and nerves were excised and imaged. Images were adjusted uniformly using the fl uorescence imaging software to achieve a dark background on the HSA-injected side, followed by measurement of the fl uorescent front from the amputated nerve on the TTc-injected side. This distance and the time after injection were used to estimate the speed of transport.
Results

Synthesis, Labeling, and Characterization of TTc
His-tag affi nity chromatography was used to purify recombinant TTc, yielding protein at a concentration of 5 mg/mL. TTc labeled with Alexa Fluor546, -680, and -790 all retained integrity and immunoreactivity after purifi cation and fl uorescent labeling in comparison with commercially available TTc ( Figure 1C ).
TTc-Alexa680 conjugate was tested on PC-12 cell cultures and demonstrated expected uptake into the cells, 20 indicating retained biologic activity compared with commercially available TTc (see Figure 1C ). In contrast, Alexa-labeled control HSA (HSA-Alexa680) showed no uptake.
In Vivo Imaging
Initial imaging experiments were directed at establishing an appropriate administration and dosing parameters and resulted in an intramuscular dose of 30 μg of TTc-Alexa790 being selected for further evaluation. Lesser doses yielded insuffi cient photon fl ux for imaging, whereas larger doses yielded nonspecifi c distribution through the body fl uids that obscured specifi c uptake (data not shown).
Subsequent whole-body fl uorescence imaging experiments were done using fl uorescently labeled TTc and HSA as a control substance at identical doses. These experiments showed that the patterns of fl uorescent agent distribution were markedly different for TTc and HSA, compatible with specifi c and fast nerve uptake for TTc and nonspecifi c diffusion for HSA. TTc-Alexa790 showed rapid and specifi c uptake and transport into spinal cords via the sciatic nerves after unilateral intramuscular injection into the calf muscles of mice over a time period of 90 minutes ( Figure 2A , right animal). In the same experiment, contralateral injections with HSA-Alexa790 did not result in nerve uptake or transport but in nonspecifi c diffusion into the body fl uids (see Figure 2A , left animal), whereas noninjected controls showed no autofl uorescence background (see Figure 2A , central animal). We also demonstrated in a different experiment the time course of uptake from the muscular injection of a single dose of 30 μg TTc-Alexa790, through the nerves and into the spine ( Figure 2B ). Nerve uptake into the spinal cord was visible within 30 minutes postinjection and became more pronounced as time progressed.
We wanted to assess the possibility that TTc might be reaching the cord through a transvascular route by diffusing into the blood from the muscular injection site rather than via direct nerve transport. To do this, we injected TTc intravenously at the same dose level (30 μg) and imaged in an identical manner. We found only diffuse body uptake and some renal clearance but no specifi c spinal uptake.
Quantitative analysis was done by drawing regions of interest (ROI) over the lumbar and thoracic areas ( Figure 2C ) . Fluorescence values over the injection site and the adjacent thighs were highly variable and discarded from analysis. TTc after intramuscular injection ( n = 5), HSA after intramuscular injection ( n = 3), and TTc after intravenous injection ( n = 4) all showed markedly different quantitative profi les, paralleling their differing imaging appearance. TTc accumulated over the spine (top two curves in Figure 2C ) but only after intramuscular injection, whereas HSA did not distribute to the spine when injected into the calf muscles in the same manner as TTc (middle two curves in Figure 2C ). Intravenous injection of TTc resulted in dilute background activity only (bottom two curves in Figure 2C ). In the thoracic region, mean fl uorescent values showed statistically signifi cant differences between TTc intramuscular and HSA intramuscular injections ( p < .05, Student t -test, two-tailed, unequal variance) at all points (from 10 to 90 minutes) excepting baseline (top and middle curves on Figure 2C , right panel). These values tended to statistical signifi cance for the lumbar area but did not reach signifi cance, likely because of increased variability induced by photon leakage from the nearby located injection site in the calf muscles.
Ex Vivo Imaging
Excised tissues from animals after TTc injection showed fl uorescent imaging features similar to those observed with in vivo imaging. When the spine was dissected and divided in cross section ( Figure 3A ), we were able to detect robust fl uorescent uptake in the cords of animals injected with TTc ( Figure 3A , right panel) but not with HSA ( Figure 3B , left panel) . Thus, the imaging fi ndings of Figure 2 , A and B, were confi rmed by the ex vivo fi ndings of Figure 3 , A and B (the same animal in each case). We noted a progressive increase in the amount of distal-to-proximal migration of TTc-related fl uorescence in the sciatic nerve as retrograde transport carried the protein up the nerve from the muscular injection site.
Histologic Analysis and Fluorescence Confocal Microscopy
Confocal imaging of whole-mounted nerves demonstrated specifi c nerve transport of TTc-Alexa680. Nerve transport was visible in the inner core or depth of the nerve and appeared to be straight linear, parallel, and nonbranching structures ( Figure 4A , left panel) as early as 20 minutes after intramuscular injection; HSA-Alexa680 was not transported ( Figure 4A , right panel) . Nonspecifi c lymphatic uptake in both TTc-Alexa680 (see Figure 4A left panel) and HSA-Alexa680 (see Figure 4A , right panel) was observed as curvilinear, nonparallel, and branched structures, located exclusively on the outer surface of the nerves. The cryosectioned nerve and cord tissue showed the presence of TTcAlexa546 ipsilateral to the site of the injection in the nerves and cords. In the cross-sectioned nerves, we observed TTcAlexa546 in the nerve ( Figure 4B , left panel) , whereas the HSA-Alexa546 control showed background levels of fl uorescence only ( Figure 4B , right panel) . Lymphatic transport was only noted close to the injection site in the popliteal fossa (see Figure 4A , left and right panels) for both TTc and HSA but was present only at the distalmost end of the nerve, close to the site of muscular injection. We did not observe lymphatic transport in the mid-or proximal nerve.
Unilateral TTc calf muscle injections produced ipsilateral TTc-related fl uorescence in the gray matter of the cord, whereas no uptake was seen for the negative HSA control. Immunofl uorescence images of TTc in the cord show extensive distribution in the cord, but especially ipsilateral to the anterior motoneurons ( Figure 4C , middle panel; Figure 4C , left panel, shows cord anatomy). TTc accumulation was intracytoplasmic in the neurons, as demonstrated with nuclear counterstained DAPI images, again supporting transport within the neurons ( Figure 4C , right panel) .
Rate of Transport
Nerves harvested at 20 and 60 minutes ( n = 5 per time point) postinjection were used to estimate the transport rate of 30 mg TTc by ex vivo imaging ( Figure 5 ). There were marked differences between HSA (see Figure 5A , top) and TTc (see Figure 5A , bottom). TTc demonstrated an advancing fl uorescent front extending in the nerve from the muscle side toward the spinal cord, whereas HSA showed background fl uorescence near the injection site that did not change over time. Plotting the distance of the fl uorescent TTc front as a function of time yielded an approximate speed of 12.1 mm/h (see Figure 5B ) , which is in agreement with published data on the fast axonal transport mechanism.
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Discussion
We demonstrated that TTc can serve as a molecular imaging agent for neurography, allowing imaging of peripheral and central nerve structures. The mechanism is based on the uptake and retrograde transport of labeled TTc along nerves after intramuscular injections and could be applied to (a) demonstrate nerve anatomy or (b) the functional status of the physiologic mechanisms of retrograde uptake and transport.
This represents the fi rst demonstration of a novel nerve imaging agent, something that is not currently available to imaging science. Nerve imaging agents have great potential for increasing our diagnostic capabilities in a wide variety of nerve diseases and thus to potentially allow a greater understanding of nerve disease and aid in the development of improved therapies.
TTc in the Literature
TTc, which is nontoxic on its own, mediates nerve uptake and retrograde transport of the intact tetanus toxin in nature, as is well known from the literature. 10, 11 The fragment can be obtained from the intact toxin by papain digestion; however, the sequencing and subsequent cloning of the fragment have now enabled the purifi cation of recombinant protein. 16 The nerve uptake and transport attributes of TTc have been exploited for years in histologic investigations, leading to its use as a nerve-tracing agent in histologic studies on excised tissues. [27] [28] [29] [30] We have built on this prior work by using modern molecular imaging technologies to make the process of nerve uptake and transport visible to imaging.
Tetanus toxin is known to be transported using the fast retrograde axonal transport mechanism. 12, 13, 31 Fast axonal transport is mediated by microtubules 32 interacting with motor proteins, kinesin for anterograde transport, [33] [34] [35] and dynein 36, 37 for retrograde transport. The natural function of the fast transport mechanism is the transport of organelles and growth factors along neuronal processes.
Limitations of the Study
We faced signifi cant challenges in quantifying TTc transport rates in vivo. Specifi cally, (a) in vivo optical imaging suffers signifi cantly from light attenuation by tissue in a nonlinear, depth-dependent manner and (b) emitted photon fl ux is in part dependent on the dose of fl uorescent agent administered. Both of these effects have a strong impact on measured photon emissions and thus on transport rate calculations. To minimize these effects, we standardized our fl uorescent imaging dose to 30 μg and chose to use excised samples, thus eliminating tissue light attenuation as a variable (see Figure 5 ). This ex vivo methodology is similar to that used by prior investigators, and our measured rates are similar to the previously published rates of fast axonal transport in general. [21] [22] [23] [24] [25] [26] The transport rate of intact tetanus toxin has been studied specifi cally previously and found to vary from 2.8 mm/h in thin autonomic nerve fi bers to 13 mm/h in large sensory nerve fi bers 31 ; our measured rate of 12.1 mm/h falls in the upper end of this range and likely refl ects the high proportion of large-diameter sensory and motor nerve fi bers in the sciatic nerve.
We found that successful imaging absolutely required agents such as TTc-Alexa790, which emit in the near-infrared (NIR), similar to the experience of other investigators. [21] [22] [23] [24] [25] Other fl uorophors emitting outside the NIR range were useful only as histologic or ex vivo imaging agents.
Alternative Transport Hypotheses
Although our fi ndings are convincing of nerve transport, alternative hypotheses should also be considered: lymphatic transport and distribution by diffusion through the blood pool.
We assessed the role of lymphatic distribution by using HSA as a control substance, as it would be expected to distribute via lymph and blood but not specifi cally via nerve transport. Confocal microscopy of excised nerves did show some lymphatic distribution of both TTc and albumin, but only close to the injection site in the calf muscles, never in the mid-to proximal nerves, where nerve uptake and lymphatic uptake might be confused with each other (see Figure 4 ) . The histologic appearance of lymphatic and nerve transport could clearly be distinguished. Lymphatic transport would also not be expected to lead to signal in the spinal cord.
We assessed the role of transvascular distribution through the blood pool by injecting TTc directly intravenously, rather than our regular intramuscular route. We found intravenous TTc signal to be weak and diluted, with no specifi c spine uptake (see Figure 2C ). This led us to discount diffusion through blood and body fl uids to the cord as a mechanism for TTc accumulation in the spine.
Having discounted both lymphatic and blood transport, and having observed TTc directly in nerve tissues, we conclude that nerve transport is the most reasonable explanation of our observations. Similar fi ndings were found for intact tetanus toxin by previous investigators using histologic methods. 38 
Nerve Imaging Applications
An imaging agent for neurography would fi ll an important gap in our imaging armamentarium as no such agent is currently available. The lack of such an agent has hampered the assessment of nerve anatomy and function. Many authors have worked previously to improve neurographic imaging techniques. [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] There have been calls for a neurographic agent to be developed, 1 and some efforts toward such an agent have previously been undertaken based on the slow axonal transport of magnetic nanoparticles. [56] [57] [58] [59] We believe that TTc or its derivatives can fi ll this gap in our armamentarium and be developed to the point where we can (a) demonstrate the anatomy of nerves (eg, during surgery where nerves are at risk) and/or (b) show the functional status of nerve uptake and transport (eg, during pressureinduced neuropathy).
This should complement and augment currently available measures of nerve function (clinical examination and electrophysiology) and anatomy (mainly MRI). Having a molecular imaging agent available could signifi cantly strengthen the contribution of imaging in the assessment of neuropathy.
It is likely that nerve imaging will access new information, not measured by current techniques, once this technology is developed suffi ciently. There are indications that retrograde transport is a primary pathologic event in many neuropathies, including diabetes, 4, 5 neurotoxic chemotherapy agents, 6 compressive neuropathy, 7, 8 amyotrophic lateral sclerosis, 9 and others. Having a means to directly assess the nerve transport function could potentially provide information of earlier phases of the pathogenesis of neuropathy and shed new light on the nature of these diseases. This, in turn, will allow (a) earlier and more successful diagnosis, (b) interventions, and (c) more effective monitoring of therapies.
Future Studies
Future studies could focus on TTc in its current form as a fl uorescent agent or extend applications to other imaging modalities.
Fluorescent nerve transport imaging in its current form could be applied in experimental animal settings to perform imaging or neuroscience research, but applications in humans would likely be limited to intraoperative settings for surgeries where nerves are at risk.
Many more human applications would be enabled if imaging modalities such as MRI, nuclear scintigraphy, and positron emission tomography were able to interrogate nerve function and anatomy. Efforts to further develop TTc in this manner are under way.
Studies on the metabolism, clearance, and toxicology of the agent will also be needed in the future.
Conclusion
We have demonstrated retrograde axonal transport by noninvasive in vivo fl uorescent imaging in animals using a molecular imaging agent based on TTc. This imaging technology has the potential to open up new avenues of research into nerve function and anatomy and could be applied both in the research setting to better our understanding of neuropathies and in improving the clinical care of patients at risk of nerve damage. Neurography, analogous to the early days of angiography, awaits the development of suitable molecular imaging agents to enable its further development; we trust that this study will serve as a contribution to that end.
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